(Press Release) Ceva Santé Animale Licenses MabGenesis’ Therapeutic Antibodies for Canine Diseases

Ceva Santé Animale S.A. (“Ceva”) and MabGenesis Inc. (“MabGenesis”) announced today that Ceva has exercised its option to an exclusive and worldwide license to MabGenesis’ therapeutic antibodies, following a successful outcome of the research collaboration using MabGenesis’ proprietary fully canine antibody library platform to explore novel antibody therapeutics. Please see the joint press release here.